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KidneyAbstract The present study was aimed to investigate the ability of quercetin (QE) to ameliorate
adverse effects of cisplatin (Cis.) on the renal tissue antioxidants by investigating the kidney anti-
oxidant gene expression and the antioxidant enzymes activity. Forty rats divided into. Control rats.
QE treated rats were orally administered 100 mg QE/kg for successive 30 days. Cis. injected rats
were administered i.p. Cis. (12 mg/kg b.w.) for 5 mutual days. Cis. + QE rats were administered
Cis. i.p. (12 mg/kg) and orally administered 100 mg QE/kg for consecutive 30 days. The obtained
results indicated that Cis. induced oxidative stress in the renal tissue. That was through induction
of free radical production, inhibition of the activity of catalase (CAT), superoxide dismutase (SOD),
glutathione peroxidase (GPx), and glutathione reductase (GR) as well their genes expression. At the
same time, vitamin E, vitamin C and reduced glutathione (GSH) levels were decreased. QE had the
ability to overcome cisplatin-induced oxidative stress through the reduction of free radical levels.
The antioxidant genes expression and antioxidant enzymes activity were induced. Finally the
vitamin E, vitamin C and GSH levels were increased. Our work, proved the renoprotective effects
of QE against oxidative stress induced by cisplatin.
ª 2014 Production and hosting by Elsevier B.V. on behalf of King Saud University. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction
Cisplatin is the best and potent chemotherapeutic agent. Cis. is
the front-line therapy for treatment of many tumors such as,ovarian, testicular, cervical, lunge and penile cancer. Cis.
therapeutic effects are dose dependant. However, high dose
of cisplatin therapy is limited due to its neuro-toxic and neph-
ro-toxic effects (Noori and Mahboobc, 2010). Neurotoxicity
arises in 50% of patients treated with Cis. (Gulec et al.,
2013). Reactive oxygen species (ROS) are continuously synthe-
sized in mitochondria. At the same time, mitochondria have
potent ROS scavenge enzymes such as SOD, CAT, GPx, GR
and GST. It is known that, Cis. accumulates in kidney epithe-
lial cells mitochondria (Santos et al., 2008). That induces the
ROS synthesis and decreases the antioxidant enzymes activities
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have a positive action on the oxidative stresses in cisplatin-
induced nephrotoxicity (Tsuji et al., 2009).
Quercetin, QE (3,30,40,5,7-pentahydroxyﬂavone) is a major
class of polyphenolic ﬂavonoid compounds; it represents
60–75% of ﬂavonoid intake. QE possesses a strong antioxidant
ability through scavenging of free radicals and binding transi-
tion metal ions, inhibiting LPO. QE protected the renal tissues
against gentamicin-induced nephrotoxicity. QE ameliorated
the histopathological alterations and normalized the kidney
biochemical markers (Abdel-Raheem et al., 2009). It has been
reported that, QE protects the renal tissues from the age-related
NF-jB activity that induces the oxidative stress. In addition,
QE protects the kidneys from the adverse effects of ischemia
through induction of xanthine dehydrogenase enzyme and
inhepation of xanthine oxidase (Faddah et al., 2012). QE
signiﬁcantly decreases LPO and improves the activity of CAT
and SODand also prevents glutathione depletion. QE protected
the heart, kidney and liver, from the oxidative stress caused by
deoxycorticosterone acetate salt. It normalized the plasma
LPO, liver and heart GSH, GST and GPx activities, and
improves kidney GST activity (Galisteo et al., 2004).2. Materials and methods
2.1. Animals
Forty male albino rats, weighing 110 ± 20 g each, were
housed in standard cages in groups of ﬁve animals per cage
under controlled conditions (temperature 25 ± 0.5 C, a
12:12 light/dark cycle), with food and water free access. All
procedures of our experiment were approved by the Medical
Research Ethics Committee of King Abdulaziz, University,
Saudi Arabia. Forty rats divided into. Control rats. QE
treated rats were orally administered 100 mg QE/kg for
successive 30 days. Cis. injected rats were administered i.p.
Cis. (12 mg/kg b.w.) for 5 mutual days. Cis. + QE rats were
administered Cis. (12 mg/kg) and orally administered 100 mg
QE/kg for consecutive 30 days.
2.2. Sampling protocol
At the end of experimental period, blood samples were col-
lected from eye vein. They were used to obtain serum for mea-
suring the kidney function parameters. Rats from all groups
were killed by decapitation and kidneys were dissected rapidly,
100 mg samples were preserved in liquid nitrogen to be used
for investigation of the expressions of SOD, CAT, GR, and
GPx genes. Kidney tissue samples of 0.5 g each were homoge-
nized in 5 ml of cold HEPES buffer, pH 7.2 and kept at
80 C till further biochemical investigations.
2.3. Biochemical investigation
The creatinine and urea levels in serum were investigated with
a speciﬁc kit (Spinreact, Bas GIRONA, Spain, cat. No.
1001111 and 1001332). Malondialdehyde (MDA) was ana-
lyzed by measuring the production of TBARS according to
the method of Buege and Aust (1978) using TBARS assay
kit (Cat. No. 10009055, Cayman, USA). Protein carbonylswere determined according to Loro et al. (2012). GSH and
tGSH were determined in the kidney homogenate, using a
kit supplied by Cayman (Cat. No. 703002, Cayman, USA)
according to the manufacturer’s instructions (Ellman, 1959).
Total antioxidant capacity (TAC) was determined using a kit
supplied by Bio-diagnostic (Cat. NO. TA 25 12, Giza, Egypt).
Following the method of Koracevic et al. (2001), SOD activity
was determined using Cayman SOD diagnostic kit (Cat. No.
706002, Cayman, USA). CAT activity was determined using
a kit (Cat. No. NWK-CAT01) purchased from Northwest Life
Science Specialties (NWLSS), Vancouver, Canada, following
the manufacturer’s instructions (Aebi, 1984). GR activity
was investigated following the method of Beutler (1969) using
a kit supplied by NWLSS (Cat. No. NWK-GR01). GPx was
determined using a kit (Cat. No. NWK-GPX01) purchased
from NWLSS following the manufacturer’s instructions
(Lawrence and Burk, 1979).
2.4. Molecular analysis
Kidney SOD, CAT, GR and GPx genes expression were quan-
tiﬁed using real time PCR. Total RNA was isolated from tissue
samples using the RNeasy Mini Kit Qiagen (Cat. No. 74104).
0.5 lg of total RNA, was used for production of cDNA using
Qiagen Long Range 2 Step RT-PCR Kit, (Cat. No. 205920).
Five lL of total cDNA was mixed with 12.5 lL of 2· SYBR
Green PCR mix with ROX from Bio-Rad and 10 pmol/lL of
each forward and reverse primer for the measured genes. The
house keeping gene b-actin was used as a constitutive control
for normalization. Primer 3 software (http://frod-
o.wi.mit.edu/cgi-bin/primer3/primer3_www.cgi) was used for
primers designed, as per the published rats SOD, CAT, GR,
GPx and b-actin genes sequences of NCBI database all primers
were provided by Sigma Aldrich (Sigma–Aldrich Chemie
GmbH, Steinheim, Germany) (Table 1). AbiPrism 7300
(Applied Biosystems, USA) was used for carrying out the
PCR reactions. The RNA concentration in each sample was
determined from the threshold cycle (Ct) values. The mRNA
expression levels were calculated relative to ß-actin gene
mRNA levels using the 2DD CT method.
3. Results
The serum creatinine and urea levels were higher in the Cis.
treated rats than the control rats, the Cis. + QE, and the
QE administered rats. The MDA, and protein carbonyl levels
in the kidney homogenate were higher in the Cis. injected rats
than the control rats, the Cis. + QE, and the QE administered
rats (Table 2). The GSH, vitamin C, vitamin E, TAC, and
tGSH levels in the kidney tissue were lower in the Cis. injected
rats than the control rats, the Cis. plus QE, and the QE admin-
istered rats (Table 3). The SOD, CAT, GR, and GPx enzymes
activities and gene expressions in the kidney tissue were lower
in the Cis. injected rats than the control rats, the Cis. plus QE,
and the QE administered rats (Tables 4 and 5). Simultaneous
administration of Cis. + QE signiﬁcantly reduced the elevated
serum creatinine, urea, MDA, and protein carbonyl in kidney
tissue. In addition, they signiﬁcantly increased the GSH, vita-
min C, vitamin E, TAC, and tGSH levels in the kidney tissue.
Moreover, they signiﬁcantly induced the gene expression and
activities of CAT, SOD, GR, and GPx enzymes in the kidney
Table 1 Primer oligonucleotide sequences of GPx, CAT, CuZnSOD and ß-actin and GR genes.
Gene Oligonucleotide sequences Size (bp) Gen ID
GPx F 50-CACAGTCCACCGTGTATGCC-30 292 S50336.1
R 50-AAGTTGGGCTCGAACCCACC-30
CAT F 50-GTCCGATTCTCCACAGTCGC-30 272 AH004967.1
R 50-CGCTGAACAAGAAAGTAACCTG-30
SOD F 50-ATGGGGACAATACACAAGGC-30 225 Z21917.1
R 50-TCATCTTGTTTCTCGTGGAC-30
ß-Actin F 50-TCACTATCGGCAATGTGCGG-30 260 NM_007393
R 50-GCTCAGGAGGAGCAATGATG-30
GR F 50-CCATGTGGTTACTGCACTTCC-30 171 NM_053906
R 50-GTTCCTTTCCTTCTCCTGAGC-30
Table 2 Effect of cisplatin and/or Quercetin on serum creatinine, urea and kidney homogenate free radicals of Albino rat.
Parameter Control QE Cisplatin Cisplatin + QE
Serum creatinine (mg/dl) 0.92 ± 0.06 0.8 ± 0.08 2.9 ± 0.2** # 0.85 ± 0.01
Serum urea (mg/dl) 50 ± 4.2 48 ± 3.4 74.5 ± 10.4**,## 54 ± 1.8
Protein carbonyls (lmol g1wt.w) 1.8 ± 0.2 1.76 ± 0.25 8 ± 0.4** ## 1.85 ± 0.22
MDA (nmol g1wt.w) 0.85 ± 0.14 0.75 ± 0.2 3 ± 0.3** # 1 ± 0.3
MDA, malondialdehyde.
** p< 0.01, statistically signiﬁcant difference from control group.
# p< 0.05, statistically signiﬁcant difference from cisplatin + QE group.
Table 4 Effect of cisplatin and/or Quercetin on antioxidant enzyme activities in kidney homogenate of albino rat.
Parameter Control QE Cisplatin Cisplatin + QE
SOD (lmol/mg.wt.w/min) 20.3 ± 1.8 23 ± 2 8.2 ± 2** # 18 ± 1.2
CAT (lmol/H2O2 decomposed/mg.wt.w/min) 798 ± 15.2 801 ± 4.5 480 ± 10
** ## 760 ± 25
GR (U/mg.wt.w) 5.3 ± 0.3 5.6 ± 0.6 2.8 ± 0.3**.# 5 ± 0.5
GPx (lmol/mg.wt.w/min) 130 ± 10 135 ± 5 46 ± 6** # 120 ± 10
SOD, superoxide dismutase; CAT, catalase enzyme; GR, glutathione reductase; GPx, glutathione peroxidase; wt.w, wet weight tissue.
***p< 0.001, statistically signiﬁcant difference from control group.
** p< 0.01, statistically signiﬁcant difference from control group.
# p< 0.05, statistically signiﬁcant difference from cisplatin + QE group.
## p< 0.01, statistically signiﬁcant difference from cisplatin + QE group.
Table 3 Effect of cisplatin and/or Quercetin on antioxidant substances in kidney homogenate of albino rat.
Parameter Control QE Cisplatin Cisplatin + QE
Vitamin E (mg/L homogenate) 624.9 ± 73 681.5 ± 243 214.7 ± 50*** # 565 ± 78.9
Vitamin C (mg/ml homogenate 25 ± 5.3 27.6 ± 5.2 12.8 ± 5.5** ## 24.9 ± 6
GSH (lmol g1 wt.w) 165 ± 10 170 ± 13 76 ± 6** ## 155 ± 26
TAC (lM g1 wt. w) 5.5 ± 0.5 6.03 ± 0.6 3 ± 0.4** ## 5.2 ± 0.2
Total glutathione (lmol g1 wt. w) 173 ± 13 180 ± 15 101 ± 8.1** ## 165 ± 16
GSSG (lmol g1 wt.w) 8 ± 0.9 10 ± 1.3 25 ± 2.5** ## 10 ± 1.4
GSH, reduced glutathione; TAC, total antioxidant capacity; wt.w; wet weight tissue.
** p< 0.01, statistically signiﬁcant difference from control group.
*** p< 0.001, statistically signiﬁcant difference from control group.
# p< 0.05, statistically signiﬁcant difference from cisplatin + QE group.
## p< 0.01, statistically signiﬁcant difference from cisplatin + QE group.
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Table 5 Effect of cisplatin and/or Quercetin on antioxidant gene expression in kidney tissue of albino rat.
Parameter Control QE Cisplatin Cisplatin + QE
SOD 1.1 ± 0.001 1.3 ± 0.011 0.55 ± 0.002*,# 0.95 ± 0.3
CAT 0.95 ± 0.002 1 ± 0.012 0.34 ± 0.001**,## 0.8 ± 0.2
GR 1 ± 0.003 1.13 ± 0.006 0.43 ± 0.03*,# 0.9 ± 0.05
GPx 1 ± 0.001 1.21 ± 0.01 5 0.6 ± 0.025*,# 1.2 ± 0.1
SOD, superoxide dismutase; CAT, catalase enzyme; GR, glutathione reductase; GPx, glutathione peroxidase; wt.w, wet weight tissue.
** p< 0.01, statistically signiﬁcant difference from control group.
# p< 0.05, statistically signiﬁcant difference from cisplatin + QE group.
## p< 0.01, statistically signiﬁcant difference from cisplatin + QE group.
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sured parameter.
4. Discussion
Cisplatin is the most used and effective tumor chemotherapeu-
tic drug. The clinical use of cisplatin is limited by the onset of
severe nephrotoxicity. The acute nephrotoxicity has occurred
in 20–30% of patients treated with cisplatin (Ronald et al.,
2010). In the recent years lots of researches have been made
to overcome this problem especially regarding the optimum
duration and dose. Various antioxidant compounds have been
used to protect the kidneys from cisplatin nephrotoxicity, espe-
cially in experimental animal models (Penelope et al., 2011).
Moreover, it is well documented that Cisplatin-induced neph-
rotoxicity is related to the reactive oxygen species (ROS).
Therefore, the potential of antioxidant in nephrotoxicity
induced by cisplatin has been tested. Many studies (Noori
and Mahboobc, 2010) have mentioned that cisplatin elevated
the levels of the kidney function biochemical markers such as
serum urea and creatinine. Consistent with these data we
observed in our study that serum creatinine and urea concen-
tration were elevated denoting the damage of the renal glome-
ruli While, the concentrations of serum creatinine and urea
were reduced in rats that were administered a combination
of cisplatin + QE. These ﬁndings may be in concord with
many other studies, which found that, antioxidant compounds
like QE overcame the elevation in plasma creatinine and urea
levels caused by cisplatin (Penelope et al., 2011). The elevated
urea and creatinine concentrations in cisplatin injected rats
could be attributed to the elevated ROS (Somani et al.,
2000). The elevated ROS attacks the membrane lipids generat-
ing the lipid peroxides, which are manifested by increased
MDA. The increased MDA in the renal tissue depleted vitamin
E, vitamin C, and GSH. GSH is important in maintenance of
the cell redox and cell membrane integrity. GSH plays an
essential role in free radical scavenging through providing
the proton for the antioxidant enzymes (Abdel-Raheem
et al., 2009). In our work, GSH, and tGSH levels were
decreased in the kidney homogenate after cisplatin administra-
tion. This ﬁnding is proved by other researchers, who have
mentioned the reduction of the renal GSH level in response
to ROS induced by cisplatin injection (Silva et al., 2001).
The most convincing explanation to GSH reduction after
cisplatin administration is the over GSH consumption in
non-enzymatic removal of ROS. Additionally, the enzymatic
oxidation of GSH with over production of GSSG by theoxidant radicals, with increasing of GSSG levels as seen in
the present study. Pretreatment with antioxidant signiﬁcantly
increases the GSH and normalizes the GSSG levels in renal tis-
sues. The recycling of GSSG to GSH is controlled by the
enzyme GR. Therefore, cisplatin may be interfered with the
GSH production by reduction of the enzyme GR activity
and/or gene expression as proved in our results and conﬁrmed
by the result of Abdel-Raheem et al. (2009). It was reported
that, QE potentiated the activities and gene expression of
GR under stress condition (Ali et al., 2014), that enhances
the recycling of GSSG back to GSH. Our ﬁndings were coor-
dinated with this result as co-administration of cisplatin + QE
induced the levels of GSH, GR activity and gene expression in
comparison with cisplatin-treated rats. Furthermore, ciplatin
induces rapid alterations in the composition of membranous
lipids that could be initiated by free radicals. This is enforced
by elevated MDA levels, the main lipid peroxidation end prod-
ucts, in ciplatin treated rat kidney (Lalila et al., 2001). We have
observed an increase in MDA and protein carbonyl levels in
the cisplatin administered rats, consistent with the previously
mentioned studies. Otherwise, the expression of SOD, GR,
CAT and GPx genes was reduced in rats that were treated with
cisplatin alone as well as the SOD, GR, CAT and GPx
enzymes activity was reduced. SOD is the enzyme that cata-
lyzes superoxide radicals reduction to H2O2. This reaction
has a 10,000-fold faster rate than spontaneous dismutation
(Abdel-Raheem et al., 2009). Inhibition of CAT, SOD, and
GPx enzymes activities and their gene expression in rats
injected with cisplatin has been previously observed (Xin
et al., 2007; Noori and Mahboobc, 2010). All these alterations
were reversed in rats that were administered QE+ cisplatin.
QE obviously, induced CAT, SOD and GPx gene expressions
as well as enhanced their enzyme activities. Additionally, QE
reduced the increased MDA and protein carbonyl levels. This
proves that QE administration overcomes the oxidative stress
by its antioxidant properties.
5. Conclusion
This work revealed on a molecular level that, QE minimized
the renal toxicity induced by cisplatin. QE decreased the serum
creatinine and urea levels. QE improved nonenzymatic antiox-
idant substances as GSH, vitamin E and vitamin C. Addition-
ally, it induced the enzymatic antioxidant system on the gene
and protein levels. The protective effect of QE against renal
damage induced by cisplatin could be explained by its antiox-
idant properties.
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